Home › Research › Biomarkers
Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio
Alicia Algeciras‐Schimnich, Joshua A. Bornhorst, Daniel J. Figdore, Ramiro Eduardo Rea Reyes, Susan Ashrafzadeh‐Kian, Rachel Wilson, Brian J. Burkett, D H Johnson et al.. JAMA Neurology, 2026-06-01
Topic: Brain proteins, microglia and lab models
This cross-sectional study evaluates the performance of the US Food and Drug Administration–cleared phosphorylated tau 217 (p-tau217) to β-amyloid 42 ratio cut points used to detect amyloid pathology associated with Alzheimer disease.
Key findings
- This cross-sectional study evaluates the performance of the US Food and Drug Administration–cleared phosphorylated tau 217 (p-tau217) to β-amyloid 42 ratio cut points used to detect amyloid pathology associated with Alzheimer disease.
Why it matters
This cross-sectional study evaluates how the FDA-cleared p-tau217 to β-amyloid 42 ratio cut points perform at detecting amyloid pathology. It is a diagnostic performance assessment and reports nothing about treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Evidence strengthLow
How this study scored 54/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA Neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 5 / 6 | Cited 24.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Ronald Carl Petersen: h-index 209 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42223932) |
| Free to read | 2 / 2 | Free to read |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2026.1565
- PubMed: 42223932
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Algeciras‐Schimnich, A., Bornhorst, J. A., Figdore, D. J., Reyes, R. E. R., Ashrafzadeh‐Kian, S., Wilson, R., et al. (2026). Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2026.1565
Vancouver
Algeciras‐Schimnich A, Bornhorst JA, Figdore DJ, Reyes RER, Ashrafzadeh‐Kian S, Wilson R, et al. Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio. JAMA Neurology. 2026. doi:10.1001/jamaneurol.2026.1565. PMID: 42223932.
BibTeX
@article{algecirasschimnich2026-42223932,
author = {Algeciras‐Schimnich, Alicia and Bornhorst, Joshua A. and Figdore, Daniel J. and Reyes, Ramiro Eduardo Rea and Ashrafzadeh‐Kian, Susan and Wilson, Rachel and Burkett, Brian J. and Johnson, D H and others},
title = {{Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio}},
journal = {JAMA Neurology},
year = {2026},
doi = {10.1001/jamaneurol.2026.1565},
pmid = {42223932},
url = {https://doi.org/10.1001/jamaneurol.2026.1565}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Biomarkers
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.